The co-primary objectives were to first demonstrate consistency of antibody responses against circumsporozoite ( CS ) protein at one month post-dose 3 for the three commercial-scale lots and second demonstrate non-inferiority of anti-CS antibody responses at one month post-dose 3 for the commercial-scale lots compared to the pilot-scale lot .